Navigation Links
Concomitant use of Perforomist & tiotropium -- significant improvements -- COPD
Date:5/20/2008

Napa, CA (May 20, 2008) Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that concomitant therapy with Perforomist Inhalation Solution (formoterol fumarate inhalation solution; FFIS), delivered by nebulization, and Spiriva (tiotropium; TIO) is significantly more effective than treatment with tiotropium alone.

Perforomist Inhalation Solution was approved in 2007 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is the only FDA-approved nebulized formoterol fumarate.

Donald P. Tashkin, MD, FACP, FCCP, Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles and lead clinical investigator, presented the results from Addition of Nebulized Formoterol Fumarate to Tiotropium Treatment Relieves Dyspnea and Symptoms in COPD Patients in a poster session today.

In this study there was a significant improvement in patients treated concomitantly with Perforomist nebulized formoterol fumarate and tiotropium over tiotropium alone, said Dr. Tashkin. These data provide physicians with a new and valuable treatment option for COPD patients with moderate to severe manifestations of the disease.

This randomized, placebo-controlled double-blind trial was conducted in 130 patients with moderate to severe COPD to evaluate the efficacy and safety of Perforomist, nebulized FFIS, when added to Spiriva maintenance treatment. Patient-centered outcomes were measured by the baseline/transitional dyspnea index, daily recording of COPD symptoms, rescue albuterol use and St. Georges Respiratory Questionnaire (SGRQ).

In this trial there was a statistical significance between the mean transitional dyspnea index scores in the Perforomist/TIO and TIO/placebo groups (2.30 and 0.16, respectively; p=0.0002). Shortness of breath, chest tightness, nighttime awakenings, and total symptom scores all improved significantly with the Perforomist/TIO treatment compared with TIO/placebo (p<0.05). Cough scores did not differ between groups. Albuterol use declined in the Perforomist/TIO group from 2.4 to1.3 puffs/day and increased in the TIO/placebo group from 2.8 to 3.4 puffs/day over six weeks; another statistically significant difference (p< 0.0001). SGRQ total scores did not change markedly from baseline or differ between groups except for the symptom domain score, which was superior in the Perforomist/TIO group compared to TIO/placebo (-6.3, p<0.04).

DEY is very pleased with the results of this study and the benefit that patients are seeing with Perforomist Inhalation Solution, said Carolyn Myers, Ph.D., President of Dey, L.P. We wish to thank Dr. Tashkin and the other members of the research team for their careful investigation into the clinical benefits of concomitant therapy of Perforomist and tiotropium. At DEY, we are committed to developing effective new treatments for serious and complex diseases, and with Perforomist are proud to provide physicians and patients a twice-daily COPD maintenance medication that offers the flexibility of dosing via nebulization.

For those attending ATS 2008, the presentation is available as follows:

Poster viewing: Session ID C42 COPD Pharmacotherapy I: Effects of Bronchodilators Tuesday, May 20, 2008, 10:45 a.m. 12:30 p.m. EDT Metro Toronto Convention Center; Area F: Halls A-B North Building, Level 300

Poster # F4: Addition of Nebulized Formoterol Fumarate to Tiotropium Treatment Relieves Dyspnea and Symptoms in COPD Patients


'/>"/>

Contact: Amy Techtmann
amy.techtmann@fkhealth.com
617-761-6784
Feinstein Kean Healthcare
Source:Eurekalert

Related medicine news :

1. Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD
2. Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
3. Perforomist-comparable pharmacokinetic and pharmacodynamic profile to DPI formulation
4. Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008
5. International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam
6. Riley Hospital for Children & Capital Institute of Pediatrics become international sister hospitals
7. IU Health & Wellness: New research findings from the Kinsey Institute
8. European Society of Human Reproduction & Embryology 24th annual meeting
9. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
10. IU Health & Wellness: Research and insights from Indiana University
11. Congressional R&D Caucus co-chairs join scientists, engineers and graduate students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... , ... Valentine’s Day is nearly upon us, and most singles could probably ... flawless hair, and a sparkling personality are all well and good, but if somebody ... home with Rover. (Actually, man’s best friend might not even want to be near ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly ... vein visualization technology should be used to ensure patient safety when placing an ... INS Standards mandate the use of vein visualization technology in patients with difficult ...
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... February 12, 2016 ... vermerkt)   http://www.sedar.com ) und ... abrufbar.    --> http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... heute seinen Konzernabschluss des zweiten Quartals ...
(Date:2/12/2016)...  Memorial Hermann Health System has teamed up with ... bring a one-of-a-kind experience to pediatric patients at ... as 360-degree video and Google Cardboard, Howard was able ... giving the patients and their families an unexpected, and ... on video . Memorial Hermann IRONMAN ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
Breaking Medicine Technology: